Skip to Content
Morningstar

Tandem Diabetes Care Inc TNDM

Morningstar Rating
Unlock
Stock XNAS Rating as of
$40.42 +0.60 (1.51%)
View Full Chart
As of Delayed Price Closed
Unlock our analysis with Morningstar Investor
Start Free Trial

Company Report

View Archive

Tandem Diabetes Poised for Return to Growth Thanks to Mobi

Debbie Wang

Though Tandem Diabetes has made a splash in the insulin pump market as the latest entrant in the US, the firm is still endeavoring to establish itself as a major competitor. On this rather lengthy path between the initial 2012 launch of its original t:slim pump and consistent positive earnings, Tandem still has a few years to go, from our perspective.

Read Full Report

Price vs Fair Value

View History
TNDM is trading at a 717% premium.
Price
$40.42
Fair Value
$62.00
Uncertainty
Very High
1-Star Price
$59.40
5-Star Price
$35.00
Economic Moat
Tfcn
Capital Allocation
Njpzrzgqs

Bulls Say, Bears Say

Bulls

Tandem’s t:slim X2 features a low-profile, color touchscreen that is very user-friendly for patients new to insulin pumps.

Bears

Medtronic arguably enjoys more accurate and advanced algorithms thanks to its far larger patient user base and proprietary data—a major reason why it remains a step ahead of Tandem in closing the loop.

Show More
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TNDM is a good fit for your portfolio.
Get 7 Days Free

News

View All

Trading Information

Previous Close Price
$39.82
Day Range
$39.43–40.55
52-Week Range
$13.82–53.69
Bid/Ask
$40.38 / $40.43
Market Cap
$2.61 Bil
Volume/Avg
726,740 / 1.6 Mil

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
3.42
Dividend Yield (Trailing)
—
Dividend Yield (Forward)
—
Total Yield
—

Company Profile

Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless pump. Nearly three-quarters of total revenue is derived from the us, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.
Sector
Healthcare
Industry
Medical Devices
Stock Style Box
Small Core
Total Number of Employees
2,400
Website
https://www.tandemdiabetes.com

Competitors

Valuation

View More
Metric
TNDM
PODD
DXCM
Price/Earnings (Normalized)
 —61.1568.50
Price/Book Value
 10.7417.4420.04
Price/Sales
 3.428.2412.71
Price/Cash Flow
 —39.9358.11
Price/Earnings
TNDM
PODD
DXCM

Financial Strength

Metric
TNDM
PODD
DXCM
Quick Ratio
 2.912.482.43
Current Ratio
 3.813.742.90
Interest Coverage
 −18.606.8832.02
Quick Ratio
TNDM
PODD
DXCM

Profitability

Metric
TNDM
PODD
DXCM
Return on Assets (Normalized)
 −10.89%7.81%10.63%
Return on Equity (Normalized)
 −33.51%30.26%30.83%
Return on Invested Capital (Normalized)
 −15.49%9.66%11.67%
Return on Assets
TNDM
PODD
DXCM
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Medical Devices Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Abbott Laboratories
ABT
CbhhtqrbYjqrgyd$181.0 Bil
 Stryker Corp
SYK
YstmhtrxVhjs$128.5 Bil
 Boston Scientific Corp
BSX
ZdtvgspjcSlzqjj$112.3 Bil
 Medtronic PLC
MDT
ZsjqbfskYrsfy$99.5 Bil
 Edwards Lifesciences Corp
EW
XvdxvlvzWcdmy$55.6 Bil
 DexCom Inc
DXCM
DlhxldbnmvZhhr$45.0 Bil
 Koninklijke Philips NV ADR
PHG
KyhkwkpSmxgrv$25.0 Bil
 Zimmer Biomet Holdings Inc
ZBH
DxqdxzjwxvDdpv$22.2 Bil
 Steris PLC
STE
ZttkxkwzCspnh$21.8 Bil
 Align Technology Inc
ALGN
VjssqypznCzhlzd$18.3 Bil

Sponsor Center